VolkerMorath (Talk | contribs) (→References) |
|||
Line 2: | Line 2: | ||
=Abstract= | =Abstract= | ||
<div class="white-box"> | <div class="white-box"> | ||
− | Biotechnology | + | Biotechnology Entrepreneurship is important for bringing beneficial scientific discoveries to the awareness and use of society. Although iGEM is an open source competition that does not in itself focus on business creation, it begs to question what the possibilities could be if it did. Entrepreneurship uses the market to find a problem and solve it. By using business methods as a scaling method, biotechnology can provide solutions for a larger variety of problems and to a greater number of people. In sum, biotech entrepreneurship is a mechanism for spreading good ideas and making useful products available to those that need them. |
Furthermore, understanding enabling factors in biotech entrepreneurship can help bring awareness to biotech and promote entrepreneurship for iGEM participants and scientists everywhere. Therefore, the aim of this research is to establish the most significant enabling factors in relation to biotech and synthetic biology (SynBio). From there, future steps can be made to promote entrepreneurship in the scientific realm. | Furthermore, understanding enabling factors in biotech entrepreneurship can help bring awareness to biotech and promote entrepreneurship for iGEM participants and scientists everywhere. Therefore, the aim of this research is to establish the most significant enabling factors in relation to biotech and synthetic biology (SynBio). From there, future steps can be made to promote entrepreneurship in the scientific realm. |
Latest revision as of 13:21, 5 January 2017
Contents
- 1 Abstract
- 2 Research Question, Research Objective and Research Design
- 3 Research Model
- 4 Literature analysis
- 5 Advising
- 6 Potential Limitations of the Data
- 7 Qualitative Data Approach
- 8 Founder Interviews
- 9 Analysis and Discussion of Founder Interviews
- 10 Non-Founder Interviews
- 11 Analysis and Discussion of Non-Founder Interviews
- 12 Summary and Discussion of Qualitative Data
- 13 Quantitative Data Approach
- 14 Quantitative Analysis
- 14.1 1. Team Characteristics
- 14.2 2. Product Characteristics
- 14.3 3. Academic and Entrepreneurial Mentorship
- 14.4 4. Access to Resources and Product Development
- 14.5 5. Access to Customer Feedback
- 14.6 6. Access to Financial Support
- 14.7 7. Access to Legal Advice and Patents
- 14.8 8. Environment, Clusters and Industry Relationship
- 14.9 9. Business Model
- 14.10 10. iGEM Enabling Factors
- 14.11 11. Full Model of Significant Variables
- 15 Summary and Discussion of Quantitative Data
- 16 Population Differences Between Founders and non-Founders
- 17 Summary and Discussion of T-Tests
- 18 Survey Open Responses
- 19 Summary and Quotes from the Survey Open Response Questions
- 20 Discussion of Qualitative and Quantitative Results
- 21 Suggestions, Next Steps and Conclusion
- 22 Survey
- 23 References
Abstract
Biotechnology Entrepreneurship is important for bringing beneficial scientific discoveries to the awareness and use of society. Although iGEM is an open source competition that does not in itself focus on business creation, it begs to question what the possibilities could be if it did. Entrepreneurship uses the market to find a problem and solve it. By using business methods as a scaling method, biotechnology can provide solutions for a larger variety of problems and to a greater number of people. In sum, biotech entrepreneurship is a mechanism for spreading good ideas and making useful products available to those that need them.
Furthermore, understanding enabling factors in biotech entrepreneurship can help bring awareness to biotech and promote entrepreneurship for iGEM participants and scientists everywhere. Therefore, the aim of this research is to establish the most significant enabling factors in relation to biotech and synthetic biology (SynBio). From there, future steps can be made to promote entrepreneurship in the scientific realm.
The analysis will begin with a presentation of the hypothesis, research model and objectives. The next sections provide a qualitative and quantitative analysis of the research. The concluding sections involve a list of suggestions and next-steps on how the data can be used for entrepreneurship.
Research Question, Research Objective and Research Design
Our theory holds that if certain enabling factors exist for biotech business creation and success, then biotech businesses will be founded. If this is true, then further research is needed to understand the enabling factors in biotech entrepreneurship in order to further promote its success. We assume that the factors that facilitate business creation and biotech innovation also extend to the realm of biotech entrepreneurship.
Research Objective 1: Establishing a theoretically grounded framework to understand the enabling factors that facilitate entrepreneurship in biotechnology.
Research Objective 2: Substantiate the theoretical framework and investigate the motives, barriers and decision criteria that leads to business creation in biotechnology and SynBio.
Research Objective 3: Establish the most important factors that lead to or prevent business creation in biotechnology and synthetic biology within the context of iGEM.
Research Model
To answer the objectives, this research draws on a combined multi-method empirical study, linking a qualitative and quantitative approach to understand entrepreneurship in biotechnology and SynBio. By combining qualitative and quantitative data, the research benefits from the advantages of both approaches. Qualitative data can capture the causal process of a certain phenomenon and substantiate the hypothesis derived from literature in order to answer research questions behind the enabling factors in biotechnology entrepreneurship [1]. On the other hand, quantitative data allows testing on a large scale as a greater spectrum of observations can be tested. This strategic combination will create a better understanding of significant factors in biotech entrepreneurship.
The next sections will establish 1) the background research used to develop the theory and structure the data collection, including literature and advising, 2) a qualitative research approach, 3) a quantitative research approach, 4) an analysis of the combined qualitative and quantitative data, a 5) a conclusion and discussion regarding enabling factors in biotech plus 6) suggestions for the biotech industry and iGEM to enable more scientists to found a company.
Literature analysis
A number of papers and books related to entrepreneurship and biotechnology were reviewed to design the survey and interview guidelines. The main literature sources include:
Literature |
Description |
Engel, Jerome S. Global Clusters of Innovation: Entrepreneurial Engines of Economic Growth around the World. 2014 |
An in-depth review and description of various entrepreneurship ecosystems around the world, as well as the enabling factors that allow startup success. |
Steinmetz, Max. Success Factors of Startups from the Founders Perspective. 2011 |
Research on success factors of startups from the point of view of business founders. |
Kananen, Johannes. Success factors of Start-up companies from the investors’ perspective. 2011 |
Research on success factors of startups from the point of view of investors. |
Journal of Comparative Policy Analysis: Research and Practice: “Where science comes to life: University bioscience, commercial spin‐offs, and regional economic development” 2014 |
Biotech entrepreneurship, university spin-offs and how they are created. |
From these sources, 11 main paradigms were established to distinguish enabling factors relevant to business creation. These paradigms cover most important influences on business creation.
Table 1: Paradigms of Entrepreneurship
Team |
Entrepreneurial experience, background, education, team spirit, risk-taking, team functionality |
Product/Project |
Characteristics of the product/project, prototyping, proof of concept, marketability of product |
Academic Mentorship |
Mentorship related to project creation, advising in biotech and in entrepreneurship, access to information, knowledge exchange, technology transfer, collaboration |
Entrepreneurial Mentorship |
Access to personal network of contacts/business angels, venture capitalists |
Access to Resources and Product Development |
Material and laboratory access, quality of test environment |
Access to Customer Feedback |
Access to feedback by potential users and customers of the product |
Access to Financial Support |
Funding via venture capitalists, accelerators, research funds, banks, university support, etc. |
Access to Legal Advice |
Advising for patenting or legal issues |
Unique Market Opportunity and Access |
Market characteristics (market competition, industry life cycle), timing of product, partners in the industry, etc. |
Environment |
Cluster for entrepreneurship and/or biotechnology, political/regulation situation |
Founder |
Characteristics of entrepreneurs, more specifically, their abilities and skills, personal motivation, vision, gender, education and work experience. *It should be noted that most of our analysis is on a “team” basis with less focus on individual founder characteristic, therefore, enabling factors related to individual characteristics are omitted in this study. |
Advising
Once the paradigms of important factors were established for entrepreneurship, experts in biotech and entrepreneurship were contacted for further consultation. The advisors included academic advisors and professors in synthetic biology, representatives of BioM (the biotech cluster in Munich, Germany), entrepreneurial advisors from the startup accelerator TechFounders and current and past participants of iGEM. All of these advisors contributed to the research methodology as well as the quantitative survey and qualitative interview design.
Research Approach
First, 11 of qualitative interviews were held to better understand the factors that affected Founders and non-Founders from the iGEM population. Second, a quantitative survey was designed to analyze the significance of different variables in business creation in biotech (specifically in iGEM). From the survey a statistical analysis was performed to measure the degree to which the variables affected founding a business.
The survey analyzes current and past iGEM participants, who are working in relatively the same, with similar education levels, time frames and resources.
Potential Limitations of the Data
Although the sample size (n = 140) is decent for data analysis, a larger sample size could potentially provide better results. Furthermore, as there were only a handful of business founded from iGEM (less than 20), the sample size of Founders from iGEM remains small due to this limitation. However, this only strengthens the reasoning for conducting research on this topic, to understand why so few teams have founded businesses and what can be improved to make it more common in the future.
Qualitative Data Approach
For the qualitative data, 12 past iGEM participants were interviewed, 4 of which founded a business (Founders) and 8 who had not (non-Founders). The goal of the interviews was to understand the Founders/non-Founders decision process and the factors that influenced or barred the way to business founding. The chapter is organized 1) a list of interviews with Founders, 2) a table of the core questions and responses from the Founders, 3) a list of interviews with non-Founders and 4) a table of the core questions and responses from the non-Founders.
Founder Interviews
Table 2: List of Founders Interviewed
INTERVIEWEE |
COMPANY |
UNIVERSITY/IGEM YEAR |
INTERVIEW DATE |
Cindy Wu |
Experiment |
U. Washington 2010 and 2011 |
September 13th, 2016 |
Danny Cabrera |
BioBots |
U. Pennsylvania |
September 20th, 2016 |
David Lloyd |
FredSense |
U. of Alberta, U. of Calgary |
September 20th, 2016 |
Eva-Maria/Jelena Aleksic |
Gene Advisor |
Edinburgh 2006 |
September 15th, 2016 |
The following table gives a snapshot of the core questions the Founder interviews sought to establish: 1) what are the enabling factors for founding a company, 2) were there adequate resources, including enough time, advising and funding to build a company, and 3) was there any knowledge or technology exchange or support from related industries.
Table 3: Core Questions and Responses from Founders
Interviewee |
What were the main reasons for founding a company? |
Did you have adequate resources? (tools, academic advising, entrepreneurship advising, time, funding) |
Did you have knowledge or technology exchange with industry members? Were you in a biotech cluster? |
Other comments on entrepreneurship in biotechnology/ synthetic biology? |
Cindy Wu |
The proof of concept at iGEM and in general was successful Initially the idea was a solution to fix their own problem Accelerators and investors were supportive |
Had adequate funding from the university during iGEM After iGEM, had very low funding until joining Y-Combinator, an accelerator in San Francisco Raised money from investors A lot of mentorship, but not business mentorship until after iGEM |
Yes. Lots of help with many CEOs, founders, universities Mentors and alumni from Y- Combinator |
At the beginning, had no business, website, sales experience. However, they were able to develop and entire project and eventually a startup from scratch and learning everything new. iGEM was definitely an enabling factor Their advantage with earning investors trust was their huge vision for their product Almost did a PhD, but glad she did not so she could do her business |
David Lloyd |
Grant funding from Deep Starter, a program for SynBio companies Good team, smart people |
Yes, enough resources and funding A lot of entrepreneurial/business advising |
Yes, a ton of knowledge exchange, less technology exchange |
iGEM was definitely an enabling factor |
Danny Cabrera |
Good business opportunity More influence founding a business than academia – ended up deferring PhD Good mentorship Funding from DreamitHealth accelerator |
Yes, very good advising in academia and business |
No, not really |
Today it is much cheaper to do biotechnology than ever before, and in some ways the barriers are much lower |
Eva-Maria/Jelena Aleksic |
Research and access to high tech, plus a good idea of a market need Industry knowledge exchange |
Not enough funding. Took bank loans to support the project |
Yes, from the Accelerate Cambridge program, the industrial community and the academic region |
The business did not really take off until finishing their PhD’s. But once they did, they switched to the business side and founded a startup. |
Analysis and Discussion of Founder Interviews
Table 4: Most Prominent Reasons for Founding a Business
Knowledge Exchange with Industry Members |
Entrepreneurship consulting |
Funding from external parties (accelerators, banks, sponsors) |
Passion to solve a problem |
Having a Quality Team |
Deferring or Finishing Academic Studies |
The Founder interviews had many similarities and differences in their stories behind business creation. While none of the reasons mentioned in Table 4 are not necessarily more significant than others, there is a general trend. First, the teams all shared a similarity of being highly ambitious in finding funding through external sources (accelerators, banks, sponsors), as well as having a large passion for their projects, sometimes even deferring their studies. Second, the teams expressed having a quality team was useful for a successful business. Third, the teams differed slightly on how much knowledge exchange they had with industry partners during their iGEM; however, once business creation became an idea the teams heavily sought out expert advising in entrepreneurship and from industry experts. Interestingly, some of the teams were not aware of their product’s advantage until later in iGEM and many had no idea about the market characteristics until they sought out industry/entrepreneurship consulting. Overall, the storyline seems that the iGEM teams found a useful idea, developed it during iGEM with quality mentorship, came to find that they required more funding and business advising to make the product viable and worked hard to secure resources to found a startup.
The Founders also gave their thoughts in regards to entrepreneurship in biotech, suggesting that 1) today it is easier than ever before to found a biotech company, because funding and resources are much more accessible and 2) iGEM is definitely an enabling factor. These suggestions will be discussed later on in the “Suggestions and Conclusion” section.
It is important to have both sides of the story. Therefore, the next section is a list of the interviews with non-Founders and the reasons they did not found a business from their iGEM projects.
Non-Founder Interviews
Table 5: List of Interviews with Non-Founders
INTERVIEWEE |
UNIVERSITY/YEAR AT IGEM |
DATE INTERVIEWED |
Axel Uran |
EPFL 2015 |
September 20th, 2016 |
Nikolaus Huwiler |
EPFL 2014 |
September 20th, 2016 |
Linnea Österber |
KTH Royal Institute of Technology 2015 |
October 4th, 2016 |
Fernando Contreras |
IGEM Sand Diego 2014 |
October 5th, 2016 |
Fabian Rohden |
TU Darmstadt 2014 and 2015 |
October 4th, 2016 |
Fernando Contreras |
U. of California San Diego, 2014 and 2015 |
October 5, 2016 |
Nicolas Krink |
iGEM Paris 2013, iGEM Freiburg iGEM 2014, Marbough 2015, iGEM Dusseldorf 2016 |
October 4th, 2016 |
Rene Hanke |
RWTH Aachen U. 2014 and 2015 |
October 18th, 2016 |
Table 6: Core Questions and Responses from Non-Founders
Interviewee |
What were the main reasons for not founding a company? |
Did you have adequate resources? (tools, advising, time, funding) |
Did you have knowledge or technology exchange with industry members? |
Other comments on entrepreneurship in biotechnology/ synthetic biology? |
Axel Uran |
Lack of time Studies were in the way Lack of motivation Lack of advising for a startup |
Adequate advising Adequate funding Adequate tools and lab space |
No, not really |
Many investors would love to fund great ideas, and there is so much opportunity in biotech/SynBio Establish an entrepreneurship incentive/track in iGEM iGEM could invite investors to the Jamboree Studies get in the way of founding a business |
Niklaus Huwiler |
Lack of time Studies Not a priority |
Lack of time Lack of advising |
No, not really More interaction with laboratories |
iGEM is great for networking Too short on time for founding a business |
Linnea Österber |
Did not have any interest Research oriented Probably not even applicable as a business |
No, lack of resources and funding Borrowed lab equipment |
No, not really |
There was a lack of business spirit and interest |
Fernando Contreras |
Lack of time Studies in the way There was not a lot of effort put into the business side |
Yes, enough funding Decent resources and advising |
Yes, there was monetary and material support, as well as sponsorship from industry members |
There needs to be more interaction with the industry, either for startup possibilities and/or even potential job opportunities Have iGEM participants focus on solving a real need, fewer “flimsy” projects |
Fabian Rohden |
Did not have a viable business concept The project was already being done essentially by companies No incentive to patent |
Yes, a lot of support for funding and mentorship |
Yes, a lot of knowledge exchange |
Some of the iGEM ideas are not possible to market iGEM participants should focus on solving real problems |
Nicolas Krink |
Studies were in the way Lack of time |
Yes, we had adequate funding and resources throughout all the teams. Occasional lack of good advising Lack of incentive for many advisors to help in iGEM |
No |
Germany is lacking a hotspot for biotech and Synbio. There is a lack of resources and lab space with adequate advising to realize projects Biology and life science students are not trained to think entrepreneurially |
Rene Hanke |
The team members had different set plans after iGEM, although some did work independently on the project post-iGEM |
Yes, also had government funding and industry funding |
Yes, but mainly with startups |
Enabling factors for biotech would include counseling regarding patent law and entrepreneurship |
Analysis and Discussion of Non-Founder Interviews
Table 7: Most Prominent Reasons for Not Founding a Business
Lack of Knowledge Exchange with Industry Members |
Lack of Entrepreneurial Advising |
Lack of time |
Lack of motivation and interest |
Project was not competitive/viable |
Studies Got in the Way |
From these interviews it is clear that there are similarities and differences among the non-founding teams. In general, the teams had a lack of knowledge exchange and consulting with mentors. If there was industry consultation, it was primarily in the form of sponsorship. Furthermore, teams had hardly any entrepreneurial consulting and many of the teams did not even consider a business, either due to not having the skills or experience, a marketable product, time and motivation, and/or the encouragement to further their project/consider a business. A common theme was the lack of time due to the need to finish academics or continue into a research-oriented position.
One notable difference among the non-founding teams was the amount of funding and resources. Some teams had quite a lot of funding/resources while others had to get by with less. They also had mixed responses regarding the quality/quantity of academic mentors.
In general, it seems that the teams varied on funding/resources/academic mentorship but were very similar in lacking knowledge exchange with industry experts and entrepreneurship mentors. A definite theme was having a lack of time and motivation with academics in the way.
The non-Founders provided very interesting ideas to encourage entrepreneurship in biotech, including 1) increasing interaction and knowledge exchange with industry members 2) providing incentive for business creation, including a) inviting investors/accelerators/incubators to iGEM, b) creating an entrepreneurship track, c) providing job opportunities with industry members, d) encouraging entrepreneurship in the life sciences, 3) encouraging iGEM participants to solve a real-world problem/seek market opportunities and 4) establish more incubators that provide the resources and advising for people to realize their projects. These suggestions will be further discussed further in the “Suggestions and Conclusion” section later on.
Summary and Discussion of Qualitative Data
The founding and non-founding teams had many differences and a few similarities between them. First, there is a large difference between the two groups and the amount of knowledge exchange and consultation that occurred. The Founding teams had far more knowledge exchange with experts and entrepreneurship advisors than the non-founding teams.
Second, the time and motivation between teams was highly varied. Some teams did not think the project was worth the time and/or their studies were in the way. Although finishing studies was a concern for both groups, the founding teams had either finished their studies or deferred them to make time for a startup. Some of the founders even went into business studies after finishing their science degrees to help their businesses.
Third, the founding teams’ ambitions pushed them to secure funding/consulting for their projects and business aspirations. Although some of the non-Founding teams did have decent funding, they did not use the resources for business creation.
One similarity among the founders and non-founders was the general lack of business experience or skills. Hardly any of the teams had previous experience in business and only a few had dabbled in the idea of founding before iGEM. This shows that not having previous business skills does not have to be a barrier to business creation. The founding teams sought out entrepreneurship consulting and learned on the way while building their products.
In conclusion, the results of the Founder and non-Founder interviews provide interesting insights into the factors that enable biotechnology entrepreneurship in iGEM. The next section uses a quantitative method approach to assess to which degree these factors truly influence founding a business.
Quantitative Data Approach
The quantitative data survey is based upon the 11 established paradigms of business creation, plus added questions to address the specifics of biotech and iGEM. The survey has 60 questions with 140 responses and was conducted between August 26th, 2016 and October 20th, 2016 with SurveyMonkey via social media and contacting current/past iGEMers via email. The majority of the questions were structured as likert scales (1-7 rating) as well as optional open answer questions.
The survey was pretested in order to check for understandability, clarification needs, and accuracy of the questions as well as the comprehensiveness of the survey and the time needed to answer its questions [3]. The pretest was conducted with academic peers, interview partners of the case study, biotechnology clusters/companies, professors and entrepreneurship consultants. The reviews from academic peers, biotech professionals and consultants also included feedback on phrasing, presentation, and the structure of the questions.
From the survey data, logistic regression analyses were conducted to examine the relationship of the established enabling variables in biotech business creation. The following sections will begin with 1) regressions based upon the established paradigms of business creation and biotechnology/iGEM, 2) a full model regression containing variables that had a 10% significance in direct relation to our dependent variable (dependent variable = Founder), 3) t-tests to analyze differences between the Founder population and non-Founder population, 4) a summary of the open answer responses and finally 5) a discussion and summary of the data. For those interested, a copy of the survey can be found at the very end of this page.
Quantitative Analysis
Before diving into the significant factors, here are some graphs representing the general trends in gender and team size of the iGEM teams that answer the survey. Overall, the respondents were split nearly 50/50 in gender. The most common team sizes had between 6-10 or 11-15 people.
Graph: Team Number
Graph: Gender of Respondents
1. Team Characteristics
Table 8: Team Characteristics
Dependent Var. |
Log Likelihood |
Number of obs |
LR chi2(2) |
Prob > chi2 |
Psuedo R2 |
Founder |
-34.698 |
140 |
17.15 |
0.0002 |
0.1982 |
Ind. Variable |
Coefficient |
Std. Err. |
Z |
P > IzI |
95% conf. Interval |
Team Entrepreneurial Spirit |
.7353056 |
.2076626 |
3.54 |
0.00 |
.328 – 1.142 |
Team Functionality |
-.445 |
.250 |
-1.78 |
0.076 |
-.9535 - .045 |
Graph: Team Percentage that Joined in Founding
A logit regression analysis was used to analyze the most significant team factors in founding a business from iGEM. In this case, the team entrepreneurial spirit and team functionality were both highly significant with p = 0.00 and 0.076, respectively. Interestingly, while it makes sense that having an entrepreneurial spirit is positively correlated with founding a business, team functionality has a negative effect with a coefficient of -0.445! This is surprising as often team functionality plays a large part in project success. Perhaps this means the team splintered off into different groups, where only some team members founded a business independent of the rest. This is evident from the survey and graph as well, showing only a few people from the original teams founded the business. From the qualitative interviews, some teams did in fact only found with a few members of the original iGEM team. Without more information on this data, however, it is hard to make accurate assumptions on why team functionality does not enable business creation in this case. On the other hand, having an entrepreneurial spirit in the team has an extremely significant relationship of ß = 0.00, with all other variables held constant, meaning the drive and motivation to found a startup enables biotech business creation. Judging from the qualitative interviews, it certainly appears true that entrepreneurial spirit played a role as the founding teams were passionate and worked hard to secure funding and resources to found a business.
2. Product Characteristics
Table 9: Product Characteristics and Market Opportunity
Dependent Var. |
Log Likelihood |
Number of obs |
LR chi2(2) |
Prob > chi2 |
Psuedo R2 |
Founder |
-38.83 |
140 |
8.88 |
0.0029 |
0.1026 |
Ind. Variable |
Coefficient |
Std. Err. |
Z |
P > IzI |
95% conf. Interval |
Market growth |
.53 |
.1953 |
2.72 |
0.007 |
.147 - -913 |
Market growth proved the most significant factor in predicting founding in terms of markets and product characteristics, with a p = 0.007 and a positive coefficient of 0.53, with all other variables held constant. This implies the Founders were relatively aware of or stumbled upon a market opportunity with their iGEM project and were able to access the market in time to found a viable business. From the qualitative interviews, some of the founders either knew during their project development that there was market growth, or only after the iGEM competition. Either way, it is clear that market growth related to a business is beneficial to founding a startup and so conducting research on the marketability of an idea could be beneficial when choosing an iGEM project.
3. Academic and Entrepreneurial Mentorship
Table 10: Academic and Entrepreneurial Mentorship
Dependent Var. |
Log Likelihood |
Number of obs |
LR chi2(2) |
Prob > chi2 |
Psuedo R2 |
Founder |
-33.96 |
140 |
18.61 |
0.000 |
0.215 |
Ind. Variable |
Coefficient |
Std. Err. |
Z |
P > IzI |
95% conf. Interval |
Entrepreneurship Consulting |
0.64 |
0.155 |
4.15 |
0.00 |
0.948 |
Entrepreneurship consulting for iGEM projects is highly significant (p = 0.0) with a positive correlation of .644, all other variables held constant. This suggests the iGEM teams that built startups were either highly influenced or attained success partially because of consulting with business/entrepreneurship advisors. Furthermore, it is apparent that founding teams in the interviews had entrepreneurship consulting, either from their mentors or from accelerators and incubators. Therefore, it can be concluded that having an entrepreneurship mentor can highly influence its founding.
4. Access to Resources and Product Development
Regressing the variables concerning enough resources, enough time and enough advising provided no significant results at the 10% level (p ≤ .10). Although potentially significant, the survey data did not provide a reliable relationship between founding business and these variables. However, taking data from the qualitative interviews, the founding teams in general did not have enough funding/resources for startup creation during iGEM and therefore either 1) received money and resources from accelerators/incubators or 2) took out bank loans 3) gained sponsorship from other companies and universities. Furthermore, some non-founding teams did have decent funding but did not use it for business founding. So while funding, time and resources do not show a reliable relationship from the quantitative data, the qualitative data shows ambitious teams sought out and secured the resources they needed, enabling them to found a business.
5. Access to Customer Feedback
Table 11: Access to Customer Feedback
Dependent Var. |
Log Likelihood |
Number of obs |
LR chi2(2) |
Prob > chi2 |
Psuedo R2 |
Founder |
-37.59 |
140 |
11.36 |
.0007 |
.1313 |
Ind. Variable |
Coefficient |
Std. Err. |
Z |
P > IzI |
95% conf. Interval |
Access to Customer Feedback |
.527 |
.162 |
3.25 |
.001 |
.209 - .846 |
Graph: Access to Customer Feedback
Access and use of customer feedback is also highly significant with a p-value of 0.001 and a positive coefficient of 0.527, all other variables held constant. This makes sense as customer feedback is very important in business creation as it directly addresses a customer’s problem, which enables the business to then build a product that solves it, developing into a viable business. Furthermore, customer feedback allows project developers to tweak the product according to changes in trends and customer needs, enabling greater product viability. However, judging from the graph, the survey respondents in general had hardly any customer feedback. This could present an area of improvement for iGEM and iGEM teams for making more successful projects and possibly businesses.
6. Access to Financial Support
Table 12: Access to Financial Support
Dependent Var. |
Log Likelihood |
Number of obs |
LR chi2(2) |
Prob > chi2 |
Psuedo R2 |
Founder |
-37.71 |
140 |
11.13 |
.0009 |
.1286 |
Ind. Variable |
Coefficient |
Std. Err. |
Z |
P > IzI |
95% conf. Interval |
Awareness of Government Funding |
.482 |
.1463 |
3.29 |
.001 |
.195 - .768 |
Interestingly, the factor that proves most significant in business creation related to financing is the awareness of government funding with a p-value of 0.001 and ß = 0.482, all other variables held constant. This can be interpreted to mean founding iGEM teams are 1) aware of government funding and can therefore take the opportunity to secure financial support, 2) are highly motivated and are seeking funding from sources outside of the university/iGEM and/or 3) are provided this information from mentors or other sources to support project development. As previously mentioned, the interviewees were very active in finding funding sources, some of which used accelerators and other sponsors. A team that is active and aware of opportunities certainly has an advantage in business creation.
7. Access to Legal Advice and Patents
Table 13: Access to Legal Advice and Patents
Dependent Var. |
Log Likelihood |
Number of obs |
LR chi2(2) |
Prob > chi2 |
Psuedo R2 |
Founder |
-34.37 |
140 |
17.79 |
.0005 |
.2055 |
Ind. Variable |
Coefficient |
Std. Err. |
Z |
P > IzI |
95% conf. Interval |
Need/Interest in Legal Advising |
.404 |
-186 |
2-17 |
.03 |
.038 - .769 |
Having an interest in Patenting |
.411 |
.204 |
2.01 |
.044 |
.011 - .812 |
Ability to Patent During iGEM |
-.417 |
.233 |
-1.76 |
.073 |
-.874 - .039 |
Patents are a unique topic in the case of biotechnology entrepreneurship as they can significantly enable or bar a startup from success. The variables represent the need/interest in legal advice, having an interest to patent and the ability to patent during iGEM project development. The need for legal advice and having a patent interest show a positive and significant relationship to founding a business (ß = 0.404 and p = 0.030, ß = 0.411 and p = 0.044, respectively). This signifies that 1) Founders are in need of legal advice because of their interest to found a business, 2) the product could require patenting to be viable and/or 3) understanding how to secure a proper patent is difficult.
On the other hand, patenting during the iGEM project development shows a negative relationship of -0.417 and p = 0.73, all variables being held constant. This negative relationship with founding implies a barrier to patent a product during iGEM. Such a barrier would explain why some teams have difficulty founding businesses during iGEM project development.
Many of the founding teams interviewed did receive legal advising from their accelerators or mentors. Only a few needed to patent, and some are still in the middle of filing for a patent. The qualitative results are mixed on needing patents to have a viable product; however, it is clear that there is a lack of legal understanding and a need to provide iGEM teams with better legal knowledge and training, if the need were to arise.
8. Environment, Clusters and Industry Relationship
Table 14: Environment, Clusters and Industry Relationship´
Dependent Var. |
Log Likelihood |
Number of obs |
LR chi2(2) |
Prob > chi2 |
Psuedo R2 |
Founder |
-35.029 |
140 |
16.49 |
0.00 |
.191 |
Ind. Variable |
Coefficient |
Std. Err. |
Z |
P > IzI |
95% conf. Interval |
Knowledge Exchange |
.653 |
.182 |
3.59 |
0.00 |
.296 - 1.01 |
Another significant factor regarding biotechnology clusters and industry support is the variable knowledge exchange with a high significance of p = 0.00 and a positive coefficient of .653, all variables being held constant. This significant and positive relationship implies interaction with biotech clusters and/or industry members is highly influential for biotech business creation, as it likely provides 1) expert insight into problems that need solving, 2) knowledge in scientific processes, 3) knowledge in business processes and/or 4) market information important for successful business creation. From the qualitative data it is clear that most of the founding teams consulted industry experts regarding their projects and business consideration. The non-Founding teams had noticeably less interaction with industry representatives. Although founding has a clear relationship with knowledge exchange, it is clear from the survey respondents that only a few iGEM teams actually collaborated with other entities and exchanged knowledge. Therefore, it appears extremely important for iGEM teams considering founding (or for iGEM success) to have knowledge exchange.
9. Business Model
Table 15: Business Model
Dependent Var. |
Log Likelihood |
Number of obs |
LR chi2(2) |
Prob > chi2 |
Psuedo R2 |
Founder |
-31.64 |
140 |
23.26 |
.000 |
.2688 |
Ind. Variable |
Coefficient |
Std. Err. |
Z |
P > IzI |
95% conf. Interval |
Having a Business Plan |
3.07 |
.707 |
4.34 |
.00 |
1.68 – 4.45 |
Graph: Business Plan
In regards to building the business model of an iGEM project, having a business plan is extremely significant with p = 0.00 and a positive coefficient of 3.07, all variables held constant. Clearly, having a business plan greatly improves the chances of an iGEM team founding. However, as seen in the graph, very few teams in iGEM actually make a business plan. The qualitative data also suggests that founding teams created a business plan during iGEM. Therefore, it can be concluded that a business plan enables iGEM teams in business founding.
10. iGEM Enabling Factors
Table 16: iGEM Enabling Factors
Dependent Var. |
Log Likelihood |
Number of obs |
LR chi2(2) |
Prob > chi2 |
Psuedo R2 |
Founder |
-38.88 |
135 |
7.78 |
.0053 |
.091 |
Ind. Variable |
Coefficient |
Std. Err. |
Z |
P > IzI |
95% conf. Interval |
Having a Successful Proof of Concept at iGEM |
.688 |
.289 |
2.41 |
.016 |
.130 – 1.267 |
In many ways, iGEM itself is an enabling factor for biotech entrepreneurship. As shown in the data, having a successful Proof of Concept at iGEM is positively related to founding a business, with a p = 0.16 and a positive coefficient of 0.698, all variables held constant. This makes sense, as proving an idea at iGEM means potential for credibility in the real world as well. If the concept is proven and there is a market opportunity, then likely there is startup potential. In general, all of the interviewed founding teams had relatively successful Proofs of Concept. Overall, this means that really having a proven idea could lead to startup creation.
11. Full Model of Significant Variables
This model represents the variables that are significant at the 10% level (p ≤ .10) when independently regressed with the dependent variable, Founder. The variables represented are 1) having a successful Proof of Concept at iGEM, 2) having a business plan for the iGEM project 3) knowledge exchange with industry members and 4) having access to customer feedback on iGEM projects.
Table 17: Full Model of Significant Variables (p ≤ .10)
Dependent Var. |
Log Likelihood |
Number of obs |
LR chi2(2) |
Prob > chi2 |
Psuedo R2 |
Founder |
-22.02 |
135 |
41.50 |
.0000 |
.485 |
Ind. Variable |
Coefficient |
Std. Err. |
Z |
P > IzI |
95% conf. Interval |
Successful Proof of Concept at iGEM |
.76 |
.35 |
2.17 |
.033 |
.07 – 1.44 |
Having a Business Plan |
3.01 |
.911 |
3.31 |
.001 |
1,22 – 4.8 |
Knowledge Exchange |
.409 |
.23 |
1.78 |
.075 |
-.414 - .861 |
Access to Customer Feedback |
.615 |
.256 |
2.4 |
.016 |
.113 – 1.118 |
These variables represent the most significant factors related to business founding in iGEM when all the variables are regressed together. Having a successful Proof of Concept at iGEM, a business plan, plenty of knowledge exchange with industry as well as enough customer feedback enables iGEM teams to move their project from the academic world to a viable product.
Summary and Discussion of Quantitative Data
In sum, the significant quantitative variables (p ≤ .10) on iGEM business creation were 1) access to customer feedback, 2) knowledge exchange with industry, 3) a team entrepreneurial spirit, 4) product market growth 5) having entrepreneurship consulting, 6) awareness of government funding, 7) an interest in legal advice 8) an interest in patenting and 9) having a successful Proof of Concept for the iGEM project. The most significant negative variables (p ≤ .10) are 1) team functionality and 2) the inability to patent during iGEM project development.
Similar to the qualitative data, founding teams used much more knowledge exchange and entrepreneurial consulting, and had an entrepreneurial drive that made them more aware of funding opportunities, market growth and legal issues.
The most interesting factors are the degree to which knowledge exchange and mentorship were so crucial in supporting iGEM entrepreneurs. Industry interaction and proper guidance for the project and business played a heavy role in developing a marketable product, securing funding, understanding patents and being aware of market opportunities.
It is surprising that team functionality did not play a larger role in the statistics. Team quality and cohesiveness is often quoted to be one of the most significant factors for startups; however, in the case if iGEM it seems to be a negative influence. This could also stem from the fact that so many teams are very large (e.g. over 20 people), and often startups begin with much fewer people. This means teams likely split up after iGEM and only a few continued the business, as seen in the qualitative interviews.
The following sections will dive a little more deeply on Founder and non-Founder differences, as well as a look at the combined qualitative and quantitative data to better understand biotech entrepreneurship enabling factors.
Population Differences Between Founders and non-Founders
To further understand the enabling factors in biotech entrepreneurship, independent samples t-tests were conducted to compare population differences between Founders and non-Founders. More specifically, research was done to understand population differences in the degree of 1) entrepreneurship consulting, 2) advising and 3) cluster support. These variables were chosen because of their significance in the previous regressions and the emphasis the interviewees put on these factors. Understanding differences in Founder and non-Founder characteristics provides further insight into enabling factors in biotech.
1. T-Test Entrepreneurship Consulting
The first t-test examined if having more (or any) entrepreneurship consulting was significant in founding a startup from iGEM. Having access to Entrepreneurship consulting proves yet again to be a very influential variable in business creation. There was a significant difference between the Founders (M = 4.07, SD = 2.21) and non-Founder (M = 1.74, SD = 1.33), conditions; t(138) = -5.56 and p = 0.00. This data completely rejects the null hypothesis and suggests Founders are much different than non-Founders in either having access to and/or effectively using entrepreneurship consulting to found.
2. T-Test: Advising
There was a significant difference between Founders having enough advising (M = 5.53, SD = 1.51) and non-Founders having enough advising (M = 4.74, SD = .146), conditions; t(138) = -1.67, p = 0.097. In line with entrepreneurship consulting, having enough advising is significantly more apparent in the Founder population than non-Founder population. This means enough advising (in academia, science, business creation, etc.) enables iGEM teams to found businesses.
3. T-Test: Cluster Support
There was a significant difference between the Founder cluster support (M = 3.61, SD = .55) and the non-Founder cluster support (M = 2.77, SD = .146) conditions; t(138) = -1.71, p = 0.089. This implies Founders had greater support from their region and/or industry members regarding their iGEM projects, leading to startup founding success.
Summary and Discussion of T-Tests
The t-tests represent differences in Founder and non-Founder population resources that could partially explain why some teams founded and others did not. The Founders had clear advantages in entrepreneurship consulting, general advising and cluster support. This implies that the interaction with advisors and industry experts provided the knowledge Founders needed to found their businesses. Therefore, proper advising and cluster support is highly influential in iGEM team business creation.
Survey Open Responses
The following section presents the open questions asked in the survey. The goal of the questions was to discover what other factors might enable or inhibit entrepreneurship that had not already been addressed in the survey. The respondents were given the option to answer freely on 1) What were other reasons for founding a business and 2) What were other reasons for not founding a business? In addition, the respondents were asked to provide suggestions on how entrepreneurship might be encouraged in biotech/SynBio/iGEM; however, for simplicity this topic will not be presented here but discussed in the “Conclusion and Suggestions” section. After discussion of the open questions, this section will then close with unique quotes from the respondents and a summary of the open responses. For the sake of focus and brevity, each topic will summarize the most common and distinguished responses gathered from the survey.
1) What were other reasons for founding a business?
- To impact society and bring change
- To solve a problem
- For research
- To gain experience
- To earn money
- A lack of biotech jobs in the region, so founded their own venture
- Passion for the project
- For Personal development
2) What were other reasons for not founding a business?
- Lack of experience and “know-how” in business creation
- Idea/project is unappealing to society
- The patent rights go to the university, not the team
- iGEM is open source, thus patenting and/or business creation is not the focus
- Lack of interest in business opportunities
- Lack of legality in certain countries
- The idea is at a very early stage
- Lack of functional prototype
- Founding is too risky
- Regulation barriers
- Laziness
Summary and Quotes from the Survey Open Response Questions
List of Quotes from Survey Respondents
The following section presents a selection of interesting quotes from the survey respondents. In general, the respondents expressed a real passion for their projects and iGEM, as well as opportunities to further develop their projects as businesses or research (or both) post-iGEM. These quotes provide a more in-depth view of the iGEM participants, their motives and passions.
“I found the purpose of the survey very interesting. Science isn't just discovering or creating things. We must notice the relevance of technology transfer. Discovering a drug that cures cancer, a bacterium that cleans CO2 or a tool that improves crops means nothing if it never reaches the market. Hopefully, iGEM will listen and try to make some changes to more directly encourage entrepreneurship during and after their competition.” – iGEM Participant, October 15th 2016
“If IGEM was all year, constantly distributing new source from different labs, constantly sequence verifying, constantly awarding parts that help a wide variety of people, how much more could get done? I think that the answer is a lot more.” – iGEM Participant, October 10th 2016
“There are many projects that could greatly improve society related to medicine, the environment, and do not go further because of the lack of support or assessment.” – iGEM Participant, October 10th 2016
Summary of Open Responses
To summarize, it appears the extra factors listed from the open responses involve the willingness and passion to solve a problem, impact society, gain experience, personal development and potential to earn money. The barriers against founding range from not having enough experience, not having a good enough idea, inability/lack of knowledge about legal issues, regulation barriers and laziness.
The quotes from iGEM participants provide a more human touch for the research objective, showing a passion and drive for progressing iGEM projects through entrepreneurship but also frustration with the barriers that prevent them. In the following section these extra factors will be discussed in parallel to the established qualitative and quantitative data.
Discussion of Qualitative and Quantitative Results
Combing the quantitative and qualitative data brings a clearer picture of what exactly influences biotech startup creation from iGEM participants. Table 18 summary of the most significant enabling factors from the quantitative and qualitative data. The “X” and “O” represent in which data the factor was significant.
Table 18: Highly Significant Enabling Factors in Biotech Entrepreneurship (iGEM)
Enabling Factor |
Qualitative Interviews |
Quantitative Survey |
Knowledge Exchange |
X | X |
Solving a problem/Market Opportunity |
X | O |
Having a Quality Team |
X | O |
Entrepreneurship Consulting |
X | X |
Academic Consulting |
O | O |
Funding from External Sources (Accelerators, VCs, Banks, etc) |
X | O |
Deferring/Finishing Academic Studies |
X | O |
Access to Customer Feedback |
X | X |
Have a Team Entrepreneurial Spirit |
X | X |
Market Growth |
X | X |
Successful iGEM Proof of Concept |
X | X |
Awareness of Government Funding |
X | X |
Needing/seeking Legal Advising/Patenting |
X | X |
Having a Business Plan |
X | X |
This data shows that the most significant variables enabling entrepreneurship in iGEM are having knowledge exchange, a problem to solve, funding (either from accelerators/incubators/loans), studies out of the way, access to customer feedback, a team entrepreneurial spirit, a successful iGEM Proof of Concept, awareness of government funding, having a business plan, consulting legal advice and entrepreneurship consulting. In addition, survey respondents noted that the passion to solve a problem, the experience and personal development and money opportunities influenced participants to found. The next steps are to establish how this information can be used to benefit iGEM participants and biotech/Synbio entrepreneurs in the future.
Suggestions, Next Steps and Conclusion
There are many factors that influence business creation in the science realm and it is difficult to capture and quantify each variable. However, with this data it is clear that some factors highly influence business creators and further development of these variables can aid in startup founding. The following table is a list of suggestions with the first column, Enabling Factors, listing the paradigms addressed in this paper, the second column, General Suggestions, listing possibilities for biotech entrepreneurship in general and the third column, iGEM Suggestions, listing recommendations from iGEM participants to encourage entrepreneurship from iGEM.
Table 19: Enabling Factors and Suggestions for Enabling Entrepreneurship
ENABLING FACTORS |
GENERAL SUGGESTIONS |
IGEM SUGGESTIONS |
Team: Inspiration, Passion and Entrepreneurial Spirit |
Incite passion and the entrepreneurial spirit |
Focus on what entrepreneurs really need. The entrepreneurial competition did not ask teams to supplement anything truly needed for business development Encourage entrepreneurship by showcasing successful biotech/Synbio startups |
Product/Project |
Encourage functional prototypes |
Encourage functional prototypes |
Access to Academic Mentorship |
Access to professionals with a deep knowledge of the industry |
Provide a talent pool of synthetics biologist at iGEM |
Access to Entrepreneurial Mentorship |
Access to professionals with commercial experience |
Provide mentorship for Synbio/biotech business activities A course or assessment or project consulting for post-iGEM actions. Teams with successful projects can get advising on how to enter the market/market characteristics/product development/etc |
Access to Customer Feedback |
Incorporating customer feedback more effectively during project development |
Implement a more realistic startup track, by providing mentors, prize incentives, realistic business consulting, an iGEM fund for successful teams, a post-iGEM assessment for teams that want to continue after iGEM |
Access to Financial Support |
Access to investors/ VC’s/Angel investors Prize for entrepreneurial ideas |
Invite VCs/investors/angel investors to the iGEM Jamboree Winning teams could receive a monetary prize or a partnership with an accelerator/incubator Provide a startup track |
Access to Legal Advice/Patents |
Access to patent trainings Reduce barriers to patent |
Provide a patent workshop Less strict rules on patents and/or discuss alternative ways to protect IP Have a non-disclosure agreement with iGEM |
Knowledge Exchange |
Access to industry members for knowledge exchange Establish partnerships with companies for more realistic projects and mentorship |
Encourage industry members to work with iGEM teams/startups Encourage more collaboration between iGEM teams to continue realistic projects |
Technology Transfer |
Encourage technology transfer among teams/clusters/iGEM |
Free/open use of iGEM parts for development of commercial products (at least for development) |
Trainings/Student Support |
Students need more support, encouragement and “know-how” for business creation and legal topics |
iGEM could provide webinars, handbooks and/or trainings on SynBio, regulation, legal issues and commercial barriers |
Environment, Government, Entrepreneurship/Biotech Clusters |
Improve regulation to enhance and protect the biotechnology industry Encourage collaboration and cluster formation |
Make iGEMers aware of government funding, if it exists |
IGEM Funding and Time |
Decrease costs of entry for biotech/SynBio competitions Allow for more time to develop project/business potential |
iGEM is very expensive to enter, making it difficult for everyone, particularly less funded universities, to even attend. This initial barrier also takes away from funding/ability/focus to found a business successfully. There should be more time for the iGEM project. Between January and October, you have to 1) establish an idea 2) make it work and 3) get funding and resources. There is just too little time to consider a business or patents. |
The next steps for future research should involve determining how these suggestions can be realized. For example, it would be useful to investigate VCs and accelerators interested in SynBio and incorporate them into the iGEM environment. Perhaps partnerships with established companies could be made to increase knowledge and technology exchange. Entrepreneurship consultants could provide training and advising for iGEM teams. Additionally, scientists need to be inspired and aware of the possibilities of founding companies from their research. These initiatives could be simultaneously progressed as the interest and knowledge in SynBio grows and innovation clusters are formed.
Helmut Schönenberger, CEO of UnternehmerTUM center of Innovation and Entrepreneurship in Munich, is an expert on building a clusters of innovation and believes it would highly benefit SynBio initiatives. According to the seasoned entrepreneur, building an ecosystem of partnerships, mentorships and inspiration for startups creates synergies that push startup potential. Today, clusters of entrepreneurship for Synbio are just at their beginnings, therefore these ecosystems need to be fostered by connecting large companies, startups, VCs and every interested party to build an effective support system for SynBio innovation. Furthermore, teaching entrepreneurship already has established methods - the problem is reaching scientists and showing them the possibilities in entrepreneurship. By creating a SynBio entrepreneurial ecosystem, which iGEM is partially doing, you create a wealth of synergies that promote SynBio startup creation and the SynBio industry overall (Schönenberger 2016).
Promoting these enabling factors and webbing a supportive ecosystem for Synbio is key to entrepreneurship and the SynBio community. Many improvements need to be made to provide scientists with the tools, mentorship, encouragement and business opportunities. The possibilities are there and growing, iGEM and scientists around the globe need only to seize the opportunity.
Survey
If you would like to see the survey we used to collect the quantitative data, check it out here: https://static.igem.org/mediawiki/2016/5/53/Muc16_Survey_Entrepreneurship.pdf
References
- ↑ (Eisenhardt 1989, Eisenhardt and Graebner 2007, Miles and Huberman 1994, Yin 1984)
- ↑ (Steinmetz 2011, Kananen 2011, Engel 2014)
- ↑ (Bortz and Döring 1996, Schnell et al. 1988)
Engel, Jerome S. Global Clusters of Innovation: Entrepreneurial Engines of Economic Growth around the World. 2014
Regional Entrepreneurial Opportunities in the Biotech Industry: Exploring the Transition from Award-winning Nascent Entrepreneurs to Real Start-ups. Accessed on June 25th, 2016 from: http://www.iwh-halle.de/d/publik/disc/25-10.pdf
Factors Influencing Small Business Startups. International Journal of Entrepreneurial Behavior and Research. Accessed on June 25th from
https://www.researchgate.net/publication/230600351_Factors_Influencing_Sma
Steinmetz, Max. Success Factors of Startups from the Founders Perspective. April 14, 2011
Kananen, Johannes. Success factors of Start-up companies from the investors’ perspective. April 14, 2011
Schwarzkopf, Christian. "Entrepreneurial Ecosystem and Entrepreneurial Fundamentals in the USA and Germany"
Fostering Innovation and Entrepreneurship (2016). Springer Gabler 2016
"Where science comes to life: University bioscience commercial spin‐offs, and regional economic development" Journal of Comparative Policy Analysis: Research and Practice. Date Accessed: October 03, 2016, from http://www.tandfonline.com/doi/abs/10.1080/13876980008412651
Eisenhardt 1989, Eisenhardt and Graebner 2007, Miles and Huberman 1994, Yin 1984. “Theory building from cases: Opportunities and Challenges.” Accessed on October 1, 2016 from https://aom.org/uploadedFiles/Publications/AMJ/Eisenhart.Graebner.2007.pdf
Bortz, Doring. Opportunism in Business. 1996
Helmut Schönenberger, personal communication, October 14th, 2016